These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Apomorphine in the treatment of Parkinson disease].
    Author: Christensen PB, Dupont E, Jensen NB.
    Journal: Ugeskr Laeger; 1991 Sep 16; 153(38):2631-4. PubMed ID: 1949272.
    Abstract:
    In later stages of the disease, patients with Parkinson's disease treated with levodopa may become severely disabled by pronounced and sudden motor fluctuations called "the on-off syndrome". In spite of optimal individual adjustment of doses and combinations, orally administered antiparkinson drugs are often not able to eliminate the off-conditions which may last from minutes to hours and sometimes are accompanied by dystonic pain. Apomorphine, a potent dopamine receptor agonist, administered subcutaneously as single injections or continuously by means of a pump, quickly passes on to striatal dopamine receptors. With suitable individually adjusted doses, a rapid, and in some cases, more stable anti-parkinson effect may be achieved. Peripheral side-effects can be avoided by concomitant treatment with domperidone. Nine levodopa treated patients with Parkinson's disease and severe on-off syndrome received apomorphine. Seven experienced considerable and long-term improvement of the disabling symptoms, and some patients reduction of levodopa and/or bromocriptine doses. Treatment with apomorphine should only be considered in patients whose on-conditions are not accompanied by pronounced dyskinesias and/or impairment of balance or to patients suffering from severe dystonic pain.
    [Abstract] [Full Text] [Related] [New Search]